Here, we describe the discovery and characterization of BI 456906, a once-weekly, injectable GCGR/GLP-1R dual agonist currently in Phase II clinical development for obesity, type 2 diabetes, and NASH. Here, GCGR is linked to obesity due to melanocortin 4 receptor deficiency.